

HHS Public Access

Biochem Pharmacol. Author manuscript; available in PMC 2015 March 26.

Published in final edited form as:

Author manuscript

Biochem Pharmacol. 2006 February 14; 71(4): 540-549. doi:10.1016/j.bcp.2005.11.010.

Structure activity and molecular modeling analyses of riboseand base-modified uridine 5^{\prime}-triphosphate analogues at the human P2Y₂ and P2Y₄ receptors

Kenneth A. Jacobson^{a,*}, Stefano Costanzi^b, Andrei A. Ivanov^a, Susanna Tchilibon^a, Pedro Besada^a, Zhan-Guo Gao^a, Savitri Maddileti^c, and T. Kendall Harden^c

^aMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

^bComputational Chemistry Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

^cDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA

Abstract

With the long-term goal of developing receptor subtype-selective high affinity agonists for the uracil nucleotide-activated P2Y receptors we have carried out a series of structure activity and molecular modeling studies of the human P2Y2 and P2Y4 receptors. UTP analogues with substitutions in the 2'-position of the ribose moiety retained capacity to activate both $P2Y_2$ and P2Y₄ receptors. Certain of these analogues were equieffective for activation of both receptors whereas 2'-amino-2'-deoxy-UTP exhibited higher potency for the P2Y₂ receptor and 2'-azido-UTP exhibited higher potency for the $P2Y_4$ receptor. 4-Thio substitution of the uracil base resulted in a UTP analogue with increased potency relative to UTP for activation of both the $P2Y_2$ and P2Y₄ receptors. In contrast, 2-thio substitution and halo- or alkyl substitution in the 5-position of the uracil base resulted in molecules that were 3–30-fold more potent at the P2Y₂ receptor than P2Y₄ receptor. 6-Aza-UTP was a P2Y₂ receptor agonist that exhibited no activity at the P2Y₄ receptor. Stereoisomers of UTPaS and 2'-deoxy-UTPaS were more potent at the P2Y₂ than P2Y₄ receptor, and the R-configuration was favored at both receptors. Molecular docking studies revealed that the binding mode of UTP is similar for both the P2Y₂ and P2Y₄ receptor binding pockets with the most prominent dissimilarities of the two receptors located in the second transmembrane domain (V90 in the P2Y₂ receptor and I92 in the P2Y₄ receptor) and the second extracellular loop (T182 in the P2Y₂ receptor and L184 in the P2Y₄ receptor). In summary, this work reveals substitutions in UTP that differentially affect agonist activity at P2Y2 versus P2Y4 receptors and in combination with molecular modeling studies should lead to chemical synthesis of new receptor subtype-selective drugs.

^{© 2005} Elsevier Inc. All rights reserved.

^{*}Corresponding author. Tel.: +1 301 496 9024; fax: +1 301 480 8422. kajacobs@helix.nih.gov (K.A. Jacobson).

Keywords

Structure activity relationship; G protein-coupled receptor; Nucleotides; Phospholipase C; Pyrimidines; Homology modeling

1. Introduction

Pharmacological effects of UTP (uridine 5'-triphosphate) and other uracil nucleotides on second messenger signaling pathways and on various tissue responses provided the initial indications of the existence of cell surface receptors that specifically recognize extracellular pyrimidines [1,2]. This concept was confirmed and extended over the past decade with the cloning of three different G protein-coupled receptors, the P2Y₂, P2Y₄ and P2Y₆ receptors [3–6] that are activated by uracil nucleotides, and by the direct demonstration of regulated release of UTP from a variety of cell types [7,8].

The P2Y₂ receptor is activated equipotently by both UTP and ATP (adenosine 5'triphosphate) and is distributed in a broad range of tissues. For example, this receptor plays important physiological roles in epithelial cells of the lung, gastrointestinal tract, eye, and other tissues [9,10]. The human P2Y₄ receptor is selectively activated by UTP, and ATP is a potent competitive antagonist at this receptor [11]. However, the P2Y₄ receptor of several other species is activated by both UTP and ATP [11–13], and therefore, it has proven difficult to differentiate the P2Y₄ receptor from the P2Y₂ receptor on the basis of its cognate agonists in, for example, rat and mouse tissues. The P2Y₆ receptor is selectively activated by UDP (uridine 5'-diphosphate), and UTP is a weak agonist or inactive at this receptor [6,14].

The existence of three different G protein-coupled receptors that recognize uracil nucleotides has made difficult the pharmacological characterization or selective activation of these receptors in native tissues. As has proved to be the case with the P2Y receptors, i.e. $P2Y_1$, $P2Y_{11}$, $P2Y_{12}$, and $P2Y_{13}$ receptors, that are activated by adenine nucleotides, the metabolism and interconversion of extracellular nucleotides add complexities to the study of uracil nucleotide-activated receptors in native tissues [15]. For example, the ectonucleoside triphosphate diphosphohydrolase, NTPDase2, converts extracellular UTP to UDP [16], whereas ectonucleoside diphosphokinase forms UTP from UDP with the transfer of the γ -phosphate from ATP [17].

Drugs that selectively activate or block the uracil nucleotide-activated P2Y receptors would provide armamentaria for circumvention of some of the problems inherent in the study of these physiologically important signaling proteins. However, receptor subtype-selective agonists or antagonists are not available for the uracil nucleotide-activated P2Y receptors [18]. Therefore, we have undertaken a series of pharmacological studies designed to systematically evaluate the effects of various modifications of the UTP structure on the capacity of analogues to activate the UTP-activated P2Y₂ and P2Y₄ receptors. Since UTP activates the human P2Y₂ and P2Y₄ receptors with similar potencies, our first goal is to identify substitutions in UTP analogues that differentially affect activity at either of these receptors. Conversely, identification of partial agonists at these receptors would open a path to synthesis of selective high affinity antagonists of the UTP-activated P2Y receptors in a

manner similar to the approach we have followed to identify a subnanomolar affinity antagonist for the ADP-activated P2Y₁ receptor [19–21]. The results reveal encouraging progress in the first of these goals. We also conducted docking studies with rhodopsin-based homology models of the P2Y₂ and P2Y₄ receptors with the goal of extending insight gained from the empirical structure activity studies to predict optimized structures that will be pursued by application of new molecular syntheses. The combination of these structure activity analyses and molecular modeling studies provides resolution of key differences in the ligand binding pockets of the P2Y₂ versus P2Y₄ receptor that will be of heuristic importance for future ligand development.

2. Materials and methods

2.1. Reagents

2'-Ara-fluoro-2'-deoxyuridine (**25**) was purchased from R.I. Chemical, Inc. (Orange, CA). All other reagents and solvents were purchased from Sigma–Aldrich (St. Louis, MO).

2.2. Uracil nucleotide analogues

Most of the nucleotide analogues studied (compounds **5–10, 12–17**, and **20**) were purchased from TriLink Biotechnologies (San Diego, CA). Compound **19** was custom synthesized by TriLink Biotechnologies and was the gift of Dr. Victor Marquez, NCI, Frederick, MD. Compounds **1–4** and 3-methyluridine (**26**) were purchased from Sigma (St. Louis, MO). Compounds **21–24** were manufactured by Axxora (San Diego, CA)/Biolog Life Science Inst. (Bremen, Germany).

2.3. Chemical synthesis

2.3.1. Chemical methods—Methods used to prepare compounds 11 and 18 are depicted schematically in Fig. 1. ¹H NMR spectra were obtained with a Varian Gemini 300 spectrometer using D_2O as a solvent. The chemical shifts are expressed as relative ppm from HOD (4.78 ppm). ³¹P NMR spectra were recorded at room temperature by use of Varian XL 300 spectrometer (121.42 MHz); orthophosphoric acid (85%) was used as an external standard. Purity of compounds was checked using a Hewlett-Packard 1100 HPLC equipped with a Luna 5 μ RP-C18(2) analytical column (250 mm \times 4.6 mm; Phenomenex, Torrance, CA). System A—linear gradient solvent system: 5 mM TBAP-CH₃CN from 80:20 to 40:60 in 20 min, then isocratic for 2 min; the flow rate was 1 mL/min. System B-linear gradient solvent system: 10 mM TEAA-CH₃CN from 100:0 to 90:10 in 20 min, then isocratic for 2min; the flow rate was 1 mL/min. Peaks were detected by UV absorption with a diode array detector. All derivatives tested for biological activity showed >99% purity in the HPLC systems. High-resolution mass measurements were performed on Micromass/Waters LCT Premier Electrospray Time of Flight (TOF) mass spectrometer coupled with a Waters HPLC system. Purification of the nucleotide analogues for biological testing was carried out on (diethylamino)ethyl (DEAE)-A25 Sephadex columns with a linear gradient (0.01–0.5 M) of 0.5 M ammonium bicarbonate as the mobile phase. Compounds 27 and 28 were additionally purified by HPLC using system C (10 mM TEAA-CH₃CN from 100:0 to 90:10 in 30 min, then isocratic for 2 min; the flow rate was 2 mL/min) with a Luna 5µ RP-C18(2) semipreparative column (250 mm \times 10.0 mm; Phenomenex, Torrance, CA).

2.3.2. General procedure for preparation of nucleoside 5'-triphosphate (compound 18)—3-Methyluridine (26) (25 mg, 0.10 mmol) and Proton Sponge (31 mg, 0.15 mmol) were dried for several hours in high vacuum and then dissolved in trimethyl phosphate (1 mL). After cooling the solution at 0 °C, phosphorous oxychloride (0.02 mL, 0.19 mmol) was added. The mixture reaction was stirred at 0 °C for 2 h. A solution of tributylammonium pyrophosphate (303 mg, 0.64 mmol) and tributylamine (0.09 mL, 0.39 mmol) in DMF (1 mL) was added and stirring was continued at 0 °C for additional 20 min. Five milliliters of 0.2 M triethylammonium bicarbonate (TEAB) solution was added, and the reaction mixture was stirred at room temperature for 45 min. Analysis of the reaction mixture by analytical HPLC (System A) indicated the formation of three compounds, the corresponding nucleotide mono-, di-, and triphosphates. The mixture was subsequently frozen and lyophilized, and the residue was purified by Sephadex-DEAE A-25 resin ionexchange column chromatography and when was necessary (compounds 27 and 28) by semipreparative HPLC as described above. The corresponding nucleotide mono-, di-, and triphosphates were collected, frozen, and lyophilized as the triethylammonium or ammonium salts. (2'R,3'R,4'S,5'R)-1-(3',4'-dihydroxy-5'-phosphoryloxymethyltetrahydrofuran-2'-yl)-3-methyl-1H-pyrimidine-2,4-dione, triethylammonium salt (27) was obtained as a white solid (6 mg, 11%). ¹H NMR (D₂O) δ 8.06 (d, J = 8.4 Hz, 1H), 6.04 (d, J = 8.1 Hz, 1H), 6.02 (d, J = 4.2 Hz, 1H), 4.37 (m, 2H), 4.28 (m, 1H), 4.07 (m, 2H), 3.30 (s, 3H); ³¹P NMR (D₂O) δ 1.88; HRMS *m*/*z* found 337.0404 (*M* – H⁺)⁻. C₁₀H₁₄N₂O₉P requires 337.0437; HPLC (System A) 7.6 min (99%), (System B) 11.5 min (99%), (2'R,3'R,4'S, 5'R)-1-(3',4'-dihydroxy-5'-diphosphoryloxymethyltetrahydro-furan-2'-yl)-3-methyl-1Hpyrimidine-2,4-dione, triethylammonium salt (28) was obtained as a white solid (1 mg, 1%). ¹H NMR (D₂O) δ 8.01 (d, J = 7.8 Hz, 1H), 6.05 (d, J = 8.1 Hz, 1H), 6.01 (d, J = 3.6 Hz, 1H), 4.41 (m, 2H), 4.27 (m, 3H), 3.31 (s, 3H); ³¹P NMR (D₂O) δ -8.68, -11.32 (d, J = 21.4 Hz); HRMS m/z found 417.0116 $(M - H^+)^-$. C₁₀H₁₅N₂O₁₂P₂ requires 417.0100; HPLC (System A) 14.3 min (99%), (System B) 12.4 min (99%). (2'R,3'R,4'S,5'R)-1-(3',4'dihydroxy-5'-triphosphoryloxymethyl-tetrahydro-furan-2'-yl)-3-methyl-1H-pyrimidine-2,4dione, ammonium salt (18) was obtained as a white solid (8 mg, 15%). ¹H NMR (D_2O) δ 7.98 (d, J = 8.1 Hz, 1H), 6.02 (m, 2H), 4.44 (m, 1H), 4.40 (m, 1H), 4.28 (m, 3H), 3.29 (s, 3H), 5.29 (s, 3H), 5.3H); ³¹P NMR (D₂O) δ -6.64 (d, J = 20.2 Hz), -10.88 (d, J = 19.5 Hz), -21.91 (t, J = 20.2 Hz); HRMS m/z found 496.9750 $(M - H^+)^-$. C₁₀H₁₆N₂O₁₅P₃ requires 496.9764; HPLC (System A) 18.3 min (99%), (System B) 13.5 min (99%).

(2'R,3'S,4'S,5'R)-1-(3'-Fluoro-4'-hydroxy-5'-triphosphoryloxymethyl-tetrahydro-furan-2'-yl)-1H-pyrimidine-2,4-dione, ammonium salt (**11**). Compound **11** (29 mg, 26%) was obtained as a white solid from 2'-ara-fluoro-2'-deoxyuridine (**25**) following the general procedure for **18**. ¹H NMR (D₂O) δ 7.93 (d, *J* = 8.1 Hz, 1H), 6.34 (d, *J* = 15.6 Hz, 1H), 5.94 (d, *J* = 8.1 Hz, 1H), 5.24 (d, *J* = 51.6 Hz, 1H), 4.60 (d, *J* = 19.5 Hz, 1H), 4.25 (m, 3H); ³¹P NMR (D₂O) δ -9.86, -11.46 (d, *J* = 19.6 Hz), -23.05; HRMS *m*/*z* found 484.9576 (*M* – H⁺)⁻. C₉H₁₃N₂O₁₄FP₃ requires 484.9564; HPLC (System A) 19.0 min (99%), (System B) 11.6 min (99%).

2.4. Assay of P2Y₂ and P2Y₄ receptor-stimulated phospholipase C activity

Stable cell lines expressing the human P2Y₂ receptor or the human P2Y₄ receptor in 1321N1 human astrocytoma cells were generated as previously described in detail [14]. Agonist-induced [³H]inositol phosphate production was measured in 1321N1 cells grown to confluence on 48-well plates. Twelve hours before the assay, the inositol lipid pool of the cells was radiolabeled by incubation in 200 μ L of serum-free inositolfree Dulbecco's modified Eagle's medium, containing 0.4 μ Ci of *myo*-[³H]inositol. No changes of medium were made subsequent to the addition of [³H]inositol. On the day of the assay, cells were challenged with 50 μ L of the five-fold concentrated solution of receptor agonists in 200 mM Hepes, pH 7.3, containing 50 mM LiCl for 20 min at 37 °C. Incubations were terminated by aspiration of the drug-containing medium and addition of 450 μ L of 150 mM NH₄OH. [³H]Inositol phosphates were isolated by ion exchange chromatography on Dowex AG 1-X8 columns as previously described [22].

2.5. Data analyses

Agonist potencies (EC₅₀ values) were obtained from concentration– response curves by non-linear regression analysis using the GraphPad software package Prism (GraphPad, San Diego, CA). All experiments were performed in triplicate assays and repeated at least three times. The results are presented as mean \pm S.E.M. from multiple experiments or in the case of concentration effect curves from a single experiment carried out with triplicate assays that were representative of results from multiple experiments.

2.6. Reconstruction of the binding pocket model

The reconstruction of the $P2Y_2$ and $P2Y_4$ receptors around UTP was performed with the InducedFit module of the Prime 1.2 homology modeling program (Schrödinger, LLC). The calculation was restricted to the residues located within 5 Å of the ligand.

2.7. Conformational analysis of UTP inside the putative binding pocket

A conformational analysis of UTP in the binding pockets of the $P2Y_2$ and $P2Y_4$ receptors was performed by means of the mixed MCMM/LMCS sampling method as implemented in Macro-Model 9.0 [23] (Schrödinger, LLC). The approach combines the Monte Carlo Multiple Minimum (MCMM) [24] and the low-mode conformational search (LMCS) [25]. All of the rotatable bonds of the ligand, as well as the ligand itself as a single body, were subjected to Monte Carlo driven rotations and translations during the conformational search. The search was performed on the ligand and the residues located within 5 Å of the ligand, while the remaining residues were conformationally frozen. The calculations were conducted with the MMFFs force field [26], using water as implicit solvent (GB/SA model [27] as implemented in MacroModel [23]) and a molecular dielectric constant of 1. The Polak-Ribier Conjugate Gradient was used for the energy minimizations with a convergence threshold of 0.05 kJ/mol/Å.

3. Results

3.1. Chemical synthesis

Synthetic methods for the preparation of nucleoside 5'-triphosphate derivatives **11** and **18** from the nucleosides of **25** and **26**, respectively, are shown in Fig. 1. The classical phosphorous oxychloride method was used for the synthesis of both derivatives [28,29]. The 5'-mono (**27**) and diphosphate (**28**) derivatives of **26** were also isolated as side products.

3.2. Pharmacological assays and structure activity relationships

The human P2Y₂ and P2Y₄ receptors were stably expressed in 1321N1 human astrocytoma cells using retroviral vectors as previously described [14]. Agonist-promoted activation of phospholipase C (PLC) was assessed in these two stable cell lines by quantification of the accumulation of [³H]inositol phosphates as described in Section 2. UTP markedly stimulated [³H]inositol phosphate accumulation to similar levels in P2Y₂ versus P2Y₄ receptor-expressing cells. Similar EC₅₀ values also were observed for UTP (**1**) for activation of the two receptors (Fig. 2 and Table 1). ATP (**2**) was two-fold less potent than UTP at the human P2Y₂ receptor, and CTP (**3a**) and GTP (**3b**) were only weakly active at this subtype. Both nucleotides were previously shown to be antagonists at the human P2Y₄ receptor [11].

Given the similar activities of UTP at the $P2Y_2$ versus $P2Y_4$ receptor, we compared the activities of a series of ribose-modified UTP analogues (**4–11**) for activation of the two receptor types. Although less potent than UTP in most cases, all 2'-substituted molecules retained capacity to maximally stimulate both receptors in the test system used. Whereas similar potencies were observed for the 2'-O-methyl-substituted (**5**) and 2'-fluoro-substituted (**9**) molecules at the $P2Y_2$ versus $P2Y_4$ receptors (Table 1), differential effects on potencies at the two receptors were observed with 2'-amino (**7**) and 2'-azido (**8**) substitutions (Fig. 2 and Table 1). That is, the potency of 2'-amino-2'-deoxyuridine-5'-triphosphate (**7**) was unchanged from UTP at the $P2Y_2$ receptor but was 16-fold less at the $P2Y_4$ receptor. Conversely, 2'-azido-substitution in **8** resulted in a greater decrease in potency at the $P2Y_2$ receptor than at the $P2Y_4$ receptor. Interestingly, existence of the 2'-hydroxyl of UTP in the arabino configuration in **10** resulted in a molecule that exhibits similar potency to UTP at the $P2Y_2$ receptor but 10-fold reduced potency at the $P2Y_4$ receptor. The only 3'-substituted molecule, 3'-O-methyluridine-5'-triphosphate (**6**), tested was inactive at both $P2Y_2$ and $P2Y_4$ receptors.

Uracil-substituted UTP analogues (12–20) also were examined. Modification of UTP with a thio moiety in the 4 position in 16 resulted in an analogue that was two-fold and three-fold more potent than UTP at the P2Y₂ and P2Y₄ receptors, respectively (Fig. 3 and Table 1). In contrast, 2-thio-substitution in 15 resulted in a molecule that was at least as potent as UTP at the P2Y₂ receptor and 5-fold less potent at the P2Y₄ receptor. Halo- or alkyl substitution in the 5-position of the base (12–14) resulted in molecules 3–10-fold more potent at the P2Y₂ receptor than the P2Y₄ receptor. Aza-substitution in the 6-position in 17 decreased potency at the P2Y₂ receptor and resulted in an analogue that was inactive at the P2Y₄ receptor. A decrease in P2Y₂ receptor potency and complete loss of activity at the P2Y₄ receptor also occurred with replacement of uracil with a pyrimidinone ring moiety, i.e. zebularine-5'-

triphosphate [30]. Conversely, attenuated agonist activity was observed at the $P2Y_2$ and $P2Y_4$ receptors with pseudouridine-5'-triphosphate (20), in which the base moiety is replaced with a reoriented uracil ring.

Phosphate side chain modification as phosphothioates was examined in the stereoisomers of UTPaS and 2'-deoxy-UTPaS (**21–24**). These phosphate side chain modifications decreased agonist potency by approximately two orders of magnitude. Both stereoisomers of UTPaS (**21, 22**) were approximately fivefold more potent at the P2Y₂ receptor than the P2Y₄ receptor (Fig. 4 and Table 1). The R-configuration was favored by both receptors by approximately three-fold over the *S*-isomer. R_p -2'-deoxy-UTPaS (**23**), although displaying a relatively large standard error, was a full agonist at the P2Y₂ receptor and inactive at the P2Y₄ receptor. S_p -2'-deoxy-UTPaS (**24**) was inactive at both the P2Y₂ and P2Y₄ receptors.

3.3. Flexible docking of UTP into putative binding pockets of the P2Y₂ and P2Y₄ receptors

We recently proposed, supported by experimental data, a hypothetical binding mode of nucleotides within P2Y receptors of subgroup A (P2Y₁, P2Y₂, P2Y₄, P2Y₆, and P2Y₁₁) [31,32]. Briefly, the cognate agonist nucleotide of each of these receptors is accommodated in the cavity defined by the third, sixth, and seventh transmembrane domains (TM) and the second extracellular loop (EL2). The ribose moiety of agonists is located between TM3 and TM7, with the negatively charged phosphate groups pointing toward TM6 and the nucleobase pointing toward TM1 and TM2.

Our previous success in identification of new receptor-selective high affinity agonists and antagonists of the P2Y₁ receptor [19–21,33] was driven in part by a close interplay of structure activity analyses, rational new drug syntheses, and molecular modeling of the P2Y₁ receptor binding site. Thus, we have carried out new modeling studies as described in Section 2 to further refine insight into the binding pocket of the P2Y₂ and P2Y₄ receptors. Our previously published binding mode [31,32] was utilized to position UTP in the putative binding pockets of the unoccupied P2Y₂ and P2Y₄ receptors. These respective binding pockets then were reconstructed around docked UTP by means of homology modeling under conditions that allowed the receptors to adapt to the presence of ligand. We subsequently performed a concerted conformational analysis of UTP and the surrounding residues, exploring simultaneously the flexibility of the ligand and the receptors. To facilitate the comparison among receptors, throughout this paper we use the GPCR residue indexing system, as explained in detail elsewhere [31].

The putative nucleotide binding pockets of the $P2Y_2$ and $P2Y_4$ receptors are highly conserved and, not surprisingly, the results of our docking experiments indicated very similar binding modes of UTP within both receptors (Fig. 5). The most prominent dissimilarities between the putative UTP binding pockets in the $P2Y_2$ and $P2Y_4$ receptors were found in residues located in TM2 (V90(2.61) in the $P2Y_2$ receptor corresponding to I92(2.61) in the $P2Y_4$ receptor) and a residue in EL2 (T182 in the $P2Y_2$ receptor corresponding to L184 in $P2Y_4$ receptor). Both of these non-conserved residues are located in proximity to the uracil moiety of UTP, and their presence results in an apparently smaller binding pocket of the $P2Y_4$ receptor for the cognate agonist.

The docking models suggested other ligand recognition elements. In agreement with observations for the P2Y₁ receptor [31,32], the triphosphate moiety of UTP is putatively coordinated by three conserved cationic residues (Fig. 5). These residues, all Arg in P2Y₂ and P2Y₄ receptors, are located in TM3 (3.29), TM6 (6.55), and TM7 (7.39). A fourth cationic residue located at the 7.36 position is in proximity to the ligand but, consistent with mutagenesis data [34], apparently does not directly interact. The NH at the 3-position of the uracil ring donates an H-bond to a Ser in TM7 (7.43). Alternatively, in other docking poses Ser(7.43) donated an H-bond to the oxygen at the 2-position of the uracil ring. This Ser residue is highly conserved within the P2Y family. Mutagenesis data revealed its fundamental role in the recognition of agonists and antagonists at the P2Y₁ receptor, where it is probably involved in the coordination of the adenine base [31].

4. Discussion

Results from this study provide the first systematic structure activity analysis designed to distinguish the P2Y₂ versus P2Y₄ receptor selectivity of base- and ribose-modified analogues of UTP. The UTP receptor selectivity of molecules with phosphate side chain modified UTP, i.e. stereoisomers of UTP α S and 2'-deoxy-UTP α S, also was examined. Thio-substitution at the 4-position increases potency at both P2Y₂ and P2Y₄ receptors, whereas other base- or ribose-modifications were identified that differentially affect the capacity of analogues to activate the P2Y₂ versus P2Y₄ receptor. These results lay the ground-work for rational drug synthesis directed at generation of high affinity agonists that selectively activate either the P2Y₂ receptor or P2Y₄ receptor.

The P2Y₂ receptor is broadly distributed in mammalian tissues, and its expression in epithelial cells of the lung, eye, and other tissues make it a potentially important therapeutic target in cystic fibrosis, eye disease, and other pathophysiologies [9,10]. Although the P2Y₄ receptor is less prominent than the P2Y₂ receptor in mammals, the presence of this signaling protein on neuronal, vascular, and epithelial tissues also makes the P2Y₄ receptor a potentially important drug target. Simultaneous expression of P2Y₂ and P2Y₄ receptors occurs in a number of cell types and tissues. These receptors theoretically can be delineated in human tissues since whereas both UTP and ATP activate the human P2Y₂ receptor, only UTP activates the human P2Y₄ receptor. However, both of these receptors are potently activated by ATP and UTP in rodents [11–13], and the complexities introduced by metabolism and interconversion of nucleotides also makes pharmacological delineation of the P2Y₂ and P2Y₄ receptors difficult in human tissues using the natural triphosphate agonists [15].

Few studies have addressed selectivity of synthetic nucleotide analogues at the $P2Y_2$ and $P2Y_4$ receptors, and no systematic comparison of structure activity relationships has been made for the $P2Y_2$ receptor versus $P2Y_4$ receptor using a unified assay system. Certain UTP analogues with substitutions in the 4-position of the base have been reported, and several of these, e.g. 4-*SH* or 4-*S*-hexyl analogues of UTP, retained potencies similar to UTP at the $P2Y_2$ receptor [35]. To our knowledge the activities of these molecules at the $P2Y_4$ receptor have not been reported. 5-Br-UTP is an agonist at both $P2Y_2$ and $P2Y_4$ receptors, but relative potencies have not been compared simultaneously in the same test system. We

previously directly compared at the human $P2Y_2$ and $P2Y_4$ receptors analogues of both UTP and ATP in which the ribose moiety was replaced by a fixed ring (methanocarba) system, i.e. a cyclopentane fused in the Northern confirmation with a cyclopropane ring [33]. (*N*)-Methanocarba UTP was equipotent to UTP at both the $P2Y_2$ and $P2Y_4$ receptors, and this analogue was approximately five-fold more potent at the $P2Y_2$ receptor than the $P2Y_4$ receptor. In contrast, whereas (*N*)-methanocarba-ATP is a very potent agonist at the human $P2Y_2$ receptor, (*N*)-methanocarba-ATP like ATP itself is inactive at the human $P2Y_4$ receptor. UTP γ S is a reasonably potent agonist at both $P2Y_2$ and $P2Y_4$ receptors [36,37]. Receptor activity also is retained in UTP analogues with imido- and methylenemodifications of the phosphate side chain [18]. Finally, both diadenosine and diuridine polyphosphate molecules are agonists at the $P2Y_2$ receptor with the most potent of these reported to be dinucleotides with four phosphates [29]. Up₄U also is a potent $P2Y_4$ receptor agonist.

The current structure activity studies provide encouraging new insight on agonist action at the P2Y₂ versus P2Y₄ receptors. Certain substitutions, e.g. thio-substitution in the 4-position of the uracil base, resulted in increases in potency at both the P2Y₂ and P2Y₄ receptors. These increases in potency are explainable on the basis of the favorable interactions that the sulfur atom establishes with hydrophobic residues from TM1, TM7, and EL2 in the binding pockets of both receptors (Fig. 5). These results strongly suggest that relative affinity can be retained or enhanced in future analogues modified in other positions to alter their P2Y receptor subtype-selectivity. The stereoselectivity in recognition of α -thiophosphate analogues of UTP showed a small but consistent preference at both P2Y₂ and P2Y₄ receptors for the R_p isomer, which is the opposite of the diastereoselectivity found at the P2Y₁ receptor [39].

A large number of modifications of the base or ribose moiety resulted in differential changes in the potency of analogues at the two receptors. Several base modifications differentially affected $P2Y_2$ receptor versus $P2Y_4$ receptor selectivity, but in all such cases $P2Y_2$ receptor potency was better retained than activity at the $P2Y_4$ receptor. As presented in Section 3,molecular modeling indicates a larger size for the base-interacting portion of the $P2Y_2$ binding pocket compared to that of the $P2Y_4$ receptor, and the observed enhancement of selectivity, for example, in the 5-substituted analogs is consistent with this predicted difference between the steric bulk tolerance of the $P2Y_2$ receptor versus the $P2Y_4$ receptor.

The observation that introduction of different functional groups in the 2' position resulted in analogues that favored the P2Y₂ receptor in some cases, e.g. 2'-amino, or the P2Y₄ receptor in another substitution, e.g. 2'-azido, suggests both subtle differences in the binding pocket of these two receptors and avenues for developing analogues that favor binding to one of these UTP-activated receptors. The 3'-OH is intramolecularly H-bonded to the β -phosphate (Fig. 5) and, according to our molecular dynamics (MD) studies on the P2Y₆–UDP complex [38], could be involved in an interaction with the cationic residues, possibly mediated by a water molecule. Therefore, substitutions at this position are likely to be detrimental for activity. Conversely, the 2'-OH apparently does not interact directly with the receptor. Hence, substitutions at this position are likely to be tolerated and can be exploited to modulate the P2Y₂/P2Y₄ receptor selectivity. The residues that interact directly with the

ribose moiety are conserved in the $P2Y_2$ and the $P2Y_4$ receptors (Fig. 5). Thus, the selectivities observed with various 2'-substituted compounds for the $P2Y_2$ or $P2Y_4$ receptors must arise from non-conserved residues located further away from the ligand that indirectly affect the shape of the binding pocket. Prolonged MD simulations of the receptor–ligand complexes in a phospholipid bilayer should reveal these residues.

In summary, these results indicate that agonist potency and $P2Y_2$ versus $P2Y_4$ receptor selectivity can be differentially modified in ribose- and base-modified analogues. Our work identifies molecules that may prove useful in pharmacologically distinguishing these receptors in complex tissues and that provide leads for rational new drug synthesis. Further evolution of molecular models for these two uracil nucleotide-activated receptors should proceed hand in hand with this novel molecule development.

Acknowledgements

We thank Dr. Victor Marquez (NCI, Frederick, MD) for the gift of zebularine 5'-triphosphate and for helpful discussion. This research was supported in part by the Intramural Research Program of the NIH, National Institute of Diabetes and Digestive and Kidney Diseases and by NIH grants GM38213 and HL34322. Susanna Tchilibon and Pedro Besada thank the Cystic Fibrosis Foundation (Bethesda, MD) for financial support. Mass spectral measurements were carried out by Dr. John Lloyd and NMR by Wesley White (NIDDK).

Abbreviations

PLC	phospholipase C
HEPES	N-(2-hydroxyethyl)-piperazine- N' -2-ethanesulfonic acid
ATP	adenosine 5'-triphosphate
СТР	cytidine 5'-triphosphate
GTP	guanosine 5'-triphosphate
TM	transmembrane domain
TBAP	tetrabutylammonium dihydrogen phosphate
TEAA	triethylammonium acetate
UDP	uridine 5'-diphosphate
UTP	uridine 5'-triphosphate

REFERENCES

- Seifert R, Schultz G. Involvement of pyrimidinoceptors in the regulation of cell functions by uridine and by uracil nucleotides. Trends Pharmacol Sci. 1989; 10:365–369. [PubMed: 2690427]
- Dubyak GR, el Moatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol. 1993; 265:C577–C606. [PubMed: 8214015]
- Lustig KD, Shiau AK, Brake AJ, Julius D. Expression cloning of an ATP receptor from mouse neuroblastoma cells. Proc Natl Acad Sci USA. 1993; 90:5113–5117. [PubMed: 7685114]
- Communi D, Pirotton S, Parmentier M, Boeynaems JM. Cloning and functional expression of a human uridine nucleotide receptor. J Biol Chem. 1995; 270:30849–30852. [PubMed: 8537336]

- Nguyen T, Erb L, Weisman GA, Marchese A, Heng HHQ, Garrad RC, et al. Cloning, expression, and chromosomal localization of the human uridine nucleotide receptor gene. J Biol Chem. 1995; 270:30845–30848. [PubMed: 8537335]
- 6. Chang K, Hanaoka K, Kumada M, Takuwa Y. Molecular cloning and functional analysis of a novel P2 nucleotide receptor. J Biol Chem. 1995; 270:26152–26158. [PubMed: 7592819]
- Lazarowski ER, Homolya L, Boucher RC, Harden TK. Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation. J Biol Chem. 1997; 272:24348–24354. [PubMed: 9305892]
- Lazarowski ER, Harden TK. Quantitation of extracellular UTP using a sensitive enzymatic assay. Br J Pharmacol. 1999; 127:1272–1278. [PubMed: 10455275]
- Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998; 50:413–492. [PubMed: 9755289]
- Lazarowski ER, Boucher RC. UTP as an extracellular signaling molecule. News Physiol Sci. 2001; 16:1–5. [PubMed: 11390937]
- Kennedy C, Qi AD, Herold CL, Harden TK, Nicholas RA. ATP, an agonist at the rat P2Y₄ receptor, is an antagonist at the human P2Y₄ receptor. Mol Pharmacol. 2000; 57:926–931. [PubMed: 10779375]
- Bogdanov YD, Wildman SS, Clements MP, King BF, Burnstock G. Molecular cloning and characterization of rat P2Y₄ nucleotide receptor. Br J Pharmacol. 1998; 124:428–430. [PubMed: 9647463]
- Webb TE, Henderson DJ, Roberts JA, Barnard EA. Molecular cloning and characterization of the rat P2Y₄ receptor. J Neurochem. 1998; 71:1348–1357. [PubMed: 9751165]
- Nicholas RA, Lazarowski ER, Watt WC, Li Q, Harden TK. Uridine nucleotide selectivity of three phospholipase C-activating P₂ receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. Mol Pharmacol. 1996; 50:224–229. [PubMed: 8700127]
- Harden TK, Lazarowski ER, Boucher RC. Release, metabolism and interconversion of adenine and uridine nucleotides: implications for G protein-coupled P2 receptor agonist selectivity. Trends Pharmacol Sci. 1997; 18:43–46. [PubMed: 9090307]
- Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn-Schmiedeberg's Arch Pharmacol. 2000; 362:299–309. [PubMed: 11111825]
- Lazarowski ER, Homolya L, Boucher RC, Harden TK. Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists. J Biol Chem. 1997; 272:20402–20407. [PubMed: 9252347]
- Müller CE. P2 pyrimidinergic receptors and their ligands. Curr Pharmaceut Des. 2002; 8:2353– 2369.
- Boyer JL, Romero T, Schachter JB, Harden TK. Identification of competitive antagonists of the P2Y₁-receptor. Mol Pharmacol. 1996; 50:1323–1329. [PubMed: 8913364]
- Boyer JL, Adams M, Ravi RG, Jacobson KA, Harden TK. 2-Chloro-N⁶-methyl-(N)methanocarba–2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y₁ receptor antagonist. Br J Pharmacol. 2002; 135:2004–2010. [PubMed: 11959804]
- 21. Kim HS, Ohno M, Xu B, Kim HO, Choi Y, Ji XD, et al. 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a Northern conformation: enhanced potency as P2Y₁ receptor antagonists. J Med Chem. 2003; 46:4974–4987. [PubMed: 14584948]
- 22. Brown HA, Lazarowski ER, Boucher RC, Harden TK. Evidence that UTP and ATP regulate phospholipase C through a common extracellular 5'-nucleotide receptor in human airway epithelial cells. Mol Pharmacol. 1991; 40:648–655. [PubMed: 1944236]
- Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufield WC, et al. MacroModel —an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem. 1990; 11:440–467.
- 24. Chang GW, Guida W, Still WC. An internal coordinate Monte-Carlo method for searching conformational space. J Am Chem Soc. 1989; 111:4379–4386.
- Kolossváry I, Guida WC. Low-mode conformational search elucidated. Application to C39H80 and flexible docking of 9-deazaguanine inhibitors to PNP. J Comput Chem. 1999; 20:1671–1684.

- Still WC, Tempczyk A, Hawlely RC, Hendrickson T. A general treatment of solvation for molecular mechanics. J Am Chem Soc. 1990; 112:6127–6129.
- Halgren TA. MMFF. VII. Characterization of mmff94, mmff94s and other widely available force fields for conformational energies and for intermolecular interaction energies and geometries. J Comput Chem. 1999; 20:730–748.
- Fischer B, Boyer JL, Hoyle CHV, Ziganshin AU, Brizzolara AL, Knight GE, et al. Identification of potent, selective P2Y-purinoceptor agonists: structure activity relationships for 2-thioether derivatives of adenosine-5'-triphosphate. J Med Chem. 1993; 36:3937–3946. [PubMed: 8254622]
- Shaver SR, Rideout JL, Pendergast W, Douglass JG, Brown EG, Boyer JL, et al. Structure–activity relationships of dinucleotides: potent and selective agonists of P2Y receptors. Purinergic Signall. 2005; 1:183–191.
- Barchi JJ Jr, Cooney DA, Hao Z, Weinberg ZH, Taft C, Marquez VE, et al. Improved synthesis of zebularine [1-(beta-d-ribofuranosyl)-dihydropyrimidin-2-one] nucleotides as inhibitors of human deoxycytidylate deaminase. J Enzyme Inhib. 1995; 9:147–162. [PubMed: 8583252]
- Costanzi S, Mamedova L, Gao Z-G, Jacobson KA. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem. 2004; 47:5393–5404. [PubMed: 15481977]
- 32. Ohno M, Costanzi S, Kim HS, Kempeneers V, Vastmans K, Herdewijn P, et al. Nucleotide analogues containing 2-oxabicyclo[2.2.1]heptane and l-α-threofuranosyl ring systems: interactions with P2Y receptors. Bioorg Med Chem. 2004; 12:5619–5630. [PubMed: 15465340]
- 33. Kim HS, Ravi RG, Marquez VE, Maddileti S, Wihlborg A-K, Erlinge D, et al. Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y₁, P2Y₂, or P2Y₄ and P2Y₁₁, but not P2Y₆ receptors. J Med Chem. 2002; 45:208–218. [PubMed: 11754592]
- 34. Erb L, Garrad R, Wang Y, Quinn T, Turner JT, Weisman GA. Site-directed mutagenesis of P2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. J Biol Chem. 1995; 270:4185–4188. [PubMed: 7876172]
- 35. Pendergast W, Yerxa BR, Douglass JG III, Shaver SR, Dougherty RW, Redick CC, et al. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates. Bioorg Med Chem Lett. 2001; 11:157–160. [PubMed: 11206448]
- Lazarowski ER, Watt WC, Stutts MJ, Brown HA, Boucher RC, Harden TK. Enzymatic synthesis of UTPγS, a potent hydrolysis resistant agonist of P_{2U}-purinoceptors. Br J Pharmacol. 1996; 17:203–209. [PubMed: 8825364]
- 37. Malmsjö M, Adner M, Harden TK, Pendergast W, Edvinsson L, Erlinge D. The stable pyrimidines UDPβS and UTPγS discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery. Br J Pharmacol. 2000; 131:51–56. [PubMed: 10960068]
- Costanzi S, Besada P, Joshi BV, Maddileti S, Mamedova L, Shin DH, et al. Human P2Y₆ receptor: Molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. J Med Chem. 2005 10.1021/jm050911p.
- Major DT, Nahum V, Wang Y, Reiser G, Fischer B. Molecular recognition in purinergic receptor.
 Diastereoselectivity of the h-P2Y₁-receptor. J Med Chem. 2004; 47:4405–4416. [PubMed: 15317453]

Jacobson et al.





Jacobson et al.



Fig. 2.

Activation of the human P2Y₂ (left panel), and P2Y₄ (right panel) receptors by ribosemodified uracil 2'-deoxynucleotide analogues containing 2'-amino (7) ($\mathbf{\nabla}$) and 2'-azido (8) ($\boldsymbol{\Delta}$) functionality. PLC activity was measured as described in Section 3.2 in 1321N1 human astrocytoma cells stably expressing the human P2Y receptors. The data are the means of triplicate determinations and are representative of results obtained in at least three separate experiments with each analog.

Jacobson et al.



Fig. 3.

Activation of the human $P2Y_2$ (left panel), and $P2Y_4$ (right panel) receptors by UTP (1) and its base-modified uracil nucleotide analogues having 5-methyl (14), 2-thio (15), and 4-thio (16) substitution. PLC activity was measured as described in Section 3.2 in 1321N1 human astrocytoma cells stably expressing the human P2Y receptors. The data are the means of triplicate determinations and are representative of results obtained in at least three separate experiments with each analog.

Jacobson et al.



Fig. 4.

Activation of the human P2Y₂ (left panel), and P2Y₄ (right panel) receptors by chiral α -phosphothioate uracil nucleotide analogues 21 (\blacktriangle), 22 (\diamondsuit), and 23 (\triangledown). PLC activity was measured as described in Section 3.2 in 1321N1 human astrocytoma cells stably expressing the human P2Y receptors. The data are the means of triplicate determinations and are representative of results obtained in three separate experiments.



Fig. 5.

Models of the complexes formed by UTP (1) with the $P2Y_2$ (a) and $P2Y_4$ (b) receptors. The nucleotide binding pockets are highly conserved in the two receptors [23]. The only two sites of divergence can be found in two residues located in TM2 and EL2 (represented with balls and sticks) in proximity to the uracil-binding pocket. To the left of each detailed binding site is a schematic representation of the entire receptor structure complexed with UTP. In the tube representations the receptor is colored according to residue positions, with a spectrum of colors that ranges from red (N-terminus) to purple (C-terminus): TM1 is in

orange, TM2 in ochre, TM3 in yellow, TM4 in green, TM4 in cyan, TM5 in blue, TM7 in purple.

Author Manuscript

In vitro pharmacological data for UTP (1) and its analogues in the stimulation of PLC at recombinant human P2Y₂ and P2Y₄ receptors expressed in astrocytoma cells

			Compounds 4 - 1' R^2 , $R^4 = 0$, unless 1 R^3 , R^5 , $R^{4RA} = H$, unless R^1 , $R^{11} = OH$, unless R^R , $R^S = \underbrace{- \dots 0}{2 - 1}$, $($, $X = CH$, unless not	9, 21 - 24 noted nless noted s noted mless noted		
Compound	Modification	Structure	EC ₅₀ at hP2Y ₂ receptor (μM) ^d	Relative to UTP	EC ₅₀ at hP2Y ₄ receptor (μM) ^α	Relative to UTP
Native ribon	ucleoside-5'-triphosphates					
1 UTP			0.049 ± 0.012	1	0.073 ± 0.02	1
2 ATP			0.085 ± 0.012	1.7	Antagonist b	
3a CTP			5.63 ± 0.30	110	Antagonist b	
3b GTP			2.64 ± 0.30	54	6.59b	90
Ribose-modi:	fied UTP analogues					
4	2'-Deoxy	$\mathbf{R}^{II}=\mathbf{H}$	1.08 ± 0.28	22	1.9 ± 0.5	26
ß	2'-Deoxy-2'-methoxy	$\mathbf{R}^{\mathrm{II}} = \mathrm{OCH}_3$	14.3 ± 7.7	290	8.2 ± 2.1	110
9	3'-Deoxy-3'-methoxy	$\mathbf{R}^{III} = \mathbf{OCH}_3$	NE	>1000	NE	>1000
7	2'-Amino-2'-deoxy	$\mathbf{R}^{II}=\mathbf{N}\mathbf{H}_2$	0.062 ± 0.008	1.3	1.2 ± 0.3	16
8	2'-Azido-2'-deoxy	$\mathbf{R}^{II} = \mathbf{N}_3$	5.0 ± 2.1	100	1.1 ± 0.1	15
6	2'-Deoxy-2'-fluoro	$\mathbf{R}^{II}=\mathbf{F}$	0.78 ± 0.11	16	0.54 ± 0.14	7.4
10	Arabino	$\mathbf{R}^{II} = \mathbf{H}, \mathbf{R}^{\mathrm{ARA}} = \mathbf{OH}$	0.087 ± 0.010	1.8	0.71 ± 0.08	9.7
11	2'-Deoxy-arabino-2'-fluoro-	$\mathbf{R}^{II} = \mathbf{H}, \mathbf{R}^{\mathrm{ARA}} = \mathbf{F}$	0.52 ± 0.15	11	0.52 ± 0.08	7.1
Uracil-modif	ied UTP analogues					
12	5-Bromo	$\mathbf{R}^{5} = \mathbf{B}\mathbf{r}$	0.75 ± 0.1	15	2.1 ± 0.7	29
13	5-Iodo	$\mathbf{R}^{5} = \mathbf{I}$	0.83 ± 0.1	17	4.0 ± 1.7	55

	o=a'-9 o=a'-9 ₽		$\begin{split} & R^3 \qquad \text{Compounds 4-1'} \\ & R^2, R^4 = O, \text{unless}, \\ & R^3, R^5, R^{NA} = H, u \\ & R^{H}, R^{H} = OH, unless \\ & R^{H}, R^{S} = \frac{-\cdots}{-\cdots} O, u \\ & R^{R}, R^{S} = \frac{-\cdots}{-\cdots} O, u \\ & X = CH, unless not \end{split}$	9, 21 - 24 noted inless noted s noted anless noted ed		
Compound	Modification	Structure	EC_{50} at hP2Y ₂ receptor (μM) ^{<i>a</i>}	Relative to UTP	EC ₅₀ at hP2Y ₄ receptor (μM) ^a	Relative to UTP
14	5-Methyl	$R^5 = CH_3$	0.48 ± 0.1	9.8	3.9 ± 1.6	53
15	2-Thio	$\mathbf{R}^2 = \mathbf{S}$	0.035 ± 0.004	0.71	0.35 ± 0.01	4.8
16	4-Thio	$\mathbf{R}^4 = \mathbf{S}$	0.026 ± 0.01	0.53	0.023 ± 0.005	0.32
17	6-Aza	$\mathbf{X} = \mathbf{N}$	8.6 ± 3.7	180	NE	>1000
18	3-Methyl	$\mathbf{R}^3 = \mathbf{CH}_3$	1.20 ± 0.20	24	3.4 ± 0.8	47
19	Zebularine analogue	$\mathbf{R}^4 = \mathbf{H}, \mathbf{H}$	8.9 ± 0.5	180	NE	>1000
20	Pseudouridine	c	0.78 ± 0.5	16	3.0 ± 0.3	41
Phosphate-mo	odified UTP analogues					
21	R _p -a-thio	$\mathbf{R}^{\mathbf{R}} = \mathbf{S}$	5.4 ± 1.5	110	27 ± 5	370
22	S_{p} - α -thio	$\mathbf{R}^{\mathbf{S}} = \mathbf{S}$	14 ± 5.5	290	81 ± 8	1100
23	2'-Deoxy-R _p -a-thio-triphosp	hate $\mathbf{R}^{\mathbf{R}} = \mathbf{S}, \mathbf{R}^{\mathbf{II}} = \mathbf{H}$	12.5 ± 6.7	260	NE	>1000
24	2'-Deoxy-S _p -α-thio triphospl	hate $\mathbf{R}^{\mathrm{S}} = \mathbf{S} \ \mathbf{R}^{\mathrm{II}} = \mathbf{H}$	NE	>1000	NE	>1000
IE - no affact a	+ 10M					

NE: no effect at 10 µM.

maximal effective concentration of reference agonist (UTP) in the same experiment. For all of the nucleotides, except 22 and 23, for which an EC50 is reported in this table, ~100% efficacy was achieved. which 50% of the maximal effect is achieved. EC50 is also expressed relative to the value for UTP at each receptor. Relative efficacies (%) were determined by comparison with the effect produced by a a Agonist potencies were calculated using a four-parameter logistic equation and the GraphPad software package (GraphPad, San Diego, CA). EC50 values (mean \pm S.E.) represent the concentration at

 b ATP antagonized the human P2Y4 receptor with a KB of 0.708 μ M. CTP (100 μ M) inhibited the response to an EC50 concentration of UTP by ~40% [11].

 c Compound **20** has the following structure:

Author Manuscript

Author Manuscript

Jacobson et al.



Author Manuscript

Author Manuscript